The full content of Annals is available to subscribers

A high rate of hepatitis C virus (HCV) infection has been reported [1] in Norwegian patients with primary hypogammaglobulinemia after treatment with intravenous immunoglobulin. The preparation involved was Gammonativ (KabiVitrim), known to have been previously contaminated with a non-A, non-B hepatitis virus [2]. Similar cases have been reported in the United States with Gammagard (Baxter Health Care, Glendale, California) and possibly Polygam (American Red Cross, Washington, D.C.) [3]. We describe a patient with hypogammaglobulinemia who developed acute HCV infection after receiving Venoglobulin-I (Alpha Therapeutic Corporation, Los Angeles, California).